Ernexa Therapeutics Inc. (ERNA) Insider Trading Activity

NASDAQ$0.285
Market Cap
$2.24M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
69 of 883
Rank in Industry
53 of 506

ERNA Insider Trading Activity

ERNA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$4,616,000
3
100
Sells
$0
0
0

Related Transactions

Cherington Charles10 percent owner
3
$4.62M
0
$0
$4.62M

About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Insider Activity of Ernexa Therapeutics Inc.

Over the last 12 months, insiders at Ernexa Therapeutics Inc. have bought $4.62M and sold $0 worth of Ernexa Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Ernexa Therapeutics Inc. have bought $7,999.87B and sold $7.5M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Cherington Charles (10 percent owner) — $4.62M.

The last purchase of 4,000,000 shares for transaction amount of $2M was made by Cherington Charles (10 percent owner) on 2026‑02‑10.

List of Insider Buy and Sell Transactions, Ernexa Therapeutics Inc.

2026-02-10PurchaseCherington Charles10 percent owner
4M
83.4958%
$0.50
$2M
-0.95%
2025-06-09PurchaseCherington Charles10 percent owner
21.24M
18.8502%
$0.10
$2.22M
-53.87%
2025-04-02PurchaseCherington Charles10 percent owner
3.77M
3.9501%
$0.10
$394,174
-50.87%
2024-10-29PurchaseCherington Charles10 percent owner
13.25M
–
$2.41M
$31,999.46B
-81.70%
2024-09-24PurchaseCherington Charles10 percent owner
13.25M
20.0594%
$0.33
$4.38M
-78.55%
2022-12-02PurchaseCherington Charlesdirector
261,756
3.9322%
$3.28
$858,560
-16.36%
2022-12-02PurchaseHALPERN JOHN Ddirector
335,920
5.0463%
$3.28
$1.1M
-16.36%
2022-12-02PurchaseSinger Nicholas Jasondirector
283,286
4.2556%
$3.28
$929,178
-16.36%
2021-07-14PurchaseDENNY GEORGE P III10 percent owner
1
<0.0001%
$11.99
$12
-69.43%
2021-07-09PurchaseDENNY GEORGE P III10 percent owner
1
<0.0001%
$14.11
$14
-70.12%
2021-07-08PurchaseDENNY GEORGE P III10 percent owner
1
<0.0001%
$14.35
$14
-71.92%
2021-07-06SaleDENNY GEORGE P III10 percent owner
75,000
5.5174%
$16.06
$1.2M
-73.58%
2021-06-17SaleCherington Charles
200,000
14.426%
$15.75
$3.15M
-67.47%
2021-06-16SaleCherington Charles
200,000
14.412%
$15.73
$3.15M
-67.72%
2020-08-13SaleELLIN ROBERT S10 percent owner
327,650
8.3217%
$5.55
$1.82M
-26.35%
2020-06-17SaleELLIN ROBERT S10 percent owner
12,400
0.3413%
$6.01
$74,524
-5.23%
2020-06-16SaleELLIN ROBERT S10 percent owner
100
0.0018%
$3.86
$386
-49.67%
2020-06-03SaleBerg Jeffrey Alan10 percent owner
21,932
0.1102%
$1.10
$24,059
+83.75%
2020-06-02SaleBerg Jeffrey Alan10 percent owner
30,730
0.1393%
$0.99
$30,423
+131.05%
2020-06-01SaleBerg Jeffrey Alan10 percent owner
30,000
0.1455%
$1.06
$31,770
+104.67%
Total: 265
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Cherington Charles10 percent owner
6779440
86.3283%
$1.93M52
<0.0001%
BROADWOOD PARTNERS, L.P.
29971561
381.653%
$8.54M150
BRADSHER NEAL C
9322262
118.7082%
$2.66M30
Trinad Capital Master Fund Ltd.10 percent owner
8900093
113.3324%
$2.54M410
Fidelity National Financial, Inc.10 percent owner
5921811
75.4074%
$1.69M015
WEST MICHAEL DCo-Chief Executive Officer
882864
11.2422%
$251,616.2431
HALPERN JOHN Ddirector
450961
5.7425%
$128,523.8910
<0.0001%
BUSH MICHAEL JCEO
300478
3.8262%
$85,636.23140
Berg Jeffrey Alan10 percent owner
276100
3.5158%
$78,688.50269
Khuchua VladimirEVP and Chief Product Officer
272700
3.4725%
$77,719.5040
Singer Nicholas Jasondirector
266214
3.3899%
$75,870.9910
<0.0001%
AWM Investment Company, Inc.10 percent owner
251562
3.2034%
$71,695.17028
Yanover Pauldirector
205000
2.6104%
$58,425.0020
LICHTINGER PEDROdirector
126250
1.6076%
$35,981.2520
Farricielli Joseph J. Jr.director
110000
1.4007%
$31,350.00150
Keymer Kenneth Ldirector
98100
1.2492%
$27,958.5030
FARRELL STEPHEN Cdirector
97450
1.2409%
$27,773.2560
Wolff AllenCFO and EVP
95500
1.2161%
$27,217.5030
MOHANTY ADITYA P.Co-Chief Executive Officer
89696
1.1422%
$25,563.3610
Santana Dario LoretoPresident and CEO
75000
0.955%
$21,375.0010
Russell Angus C.director
67500
0.8595%
$19,237.5010
Simtob Richard Isaacdirector
52088
0.6633%
$14,845.0830
CLASEN ROBERT Bdirector
50000
0.6367%
$14,250.0010
SCHLACHET DAVIDdirector
32050
0.4081%
$9,134.2510
Bourbiel JenniferVice President, Marketing
15000
0.191%
$4,275.0010
Mitgang Stevedirector
15000
0.191%
$4,275.0020
ARLEN GARY Hdirector
10450
0.1331%
$2,978.2510
COHEN ABRAHAM Edirector
10000
0.1273%
$2,850.0010
Lewis Mary Bethdirector
10000
0.1273%
$2,850.0010
Glassman Nicholas AEVP of Product and Technology
10000
0.1273%
$2,850.0010
Uphoff Tonydirector
9600
0.1222%
$2,736.0010
GARCIA PETER SChief Financial Officer
7000
0.0891%
$1,995.0020
Krishnan RamCEO
5900
0.0751%
$1,681.5040
Miller Dave BrianSVP Marketing
5600
0.0713%
$1,596.0060
TEW WILLIAM P PHDChief Commercial Officer
3265
0.0416%
$930.5305
SKIBSTED RUSSELLChief Financial Officer
2000
0.0255%
$570.0010
George Christopher AllenSVP and CHIEF INFORMATION OFF
600
0.0076%
$171.0010
BERGER FRANKLIN Mdirector
500
0.0064%
$142.5010
ELLIN ROBERT S10 percent owner
421
0.0054%
$119.99214
DENNY GEORGE P III10 percent owner
3
0%
$0.8631
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$1,848,072
66
-14.67%
$1.89M
$53,490,060
55
19.35%
$3.28M
$1,138,733
28
-4.94%
$3.34M
$337,688
19
-33.30%
$2.36M
$8,079,884
14
-43.20%
$1.33M
$82,890
11
-16.74%
$1.82M
$389,864
11
12.52%
$2.51M
$105,917
11
-28.06%
$2.42M
$18,269
10
-21.15%
$2.61M
$126,023
10
-66.17%
$1.65M
Eterna Therapeutics Inc.
(ERNA)
$7,268,979
7
-48.44%
$2.24M
$245,000
7
-62.00%
$2.14M
$70,828
6
-57.96%
$1.67M
$726,438
4
-72.85%
$1.3M
$149,778
4
-45.16%
$3.24M
$19,863
1
144.27%
$991,933.00
$9,963
1
-14.25%
$2.27M
$37,000
1
79.42%
$3.75M
$1,049,630
1
-74.91%
$851,946.00

ERNA Institutional Investors: Active Positions

Increased Positions6+40%41,969+8.12%
Decreased Positions4-26.67%36,199-7%
New Positions3New14,029New
Sold Out Positions3Sold Out36,152Sold Out
Total Postitions17+13.33%522,698+1.12%

ERNA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Corient Private Wealth Llc$508.005.48%438,092+420,569+2,400.1%2025-09-30
Susquehanna International Group, Llp$36.000.39%30,854+30,854New2025-09-30
Geode Capital Management, Llc$24.000.26%20,453+378+1.88%2025-09-30
Vanguard Group Inc$13.000.14%11,147+11,147New2025-09-30
Sippican Capital Advisors$12.000.13%10,00000%2025-09-30
Tower Research Capital Llc (Trc)$6.000.07%5,182+5,182New2025-09-30
Blackrock, Inc.$1.000.01%82000%2025-09-30
Assetmark, Inc$0<0.01%13300%2025-09-30
Eversource Wealth Advisors, Llc$0<0.01%11600%2025-09-30
Morgan Stanley$0<0.01%77-477-86.1%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.